PharmacoEpidemiology Group (PEG) conducts research in the areas prescription drug utilization, epidemiological research methods, evaluation of drug policy and educational interventions, and drug safety and effectiveness. Selected journal articles and reports co-authored by PEG members are listed below.
Dormuth CR, Kim JD, Fisher A, Piszczek J, Kuo IF. Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications. JAM
Carney G, Maclure M, Patrick DM, Fisher A, Stanley D, et al. A cluster randomized trial assessing the impact of personalized prescribing feedback on antibiotic prescribing for unco
Kim JD, Fisher A, Dormuth CR. Trends in antihypertensive drug utilization in British Columbia, 2004–2019: a descriptive study. CMAJ Open 2023; 11(4):E662-E671. DOI: 10.9778/cmajo
The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. A team of investigators from the Canadian Network for Observational Drug Effect Studies (C
On September 5, 2019, British Columbia announced a new policy to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases (IBD). Subsequently,
The results of many clinical trials are not publicly reported, or reported only after a long delay. Why? Dr. Richard Morrow explored the views of trial participants, scientists, an
Greg Carney, Jason D Kim, Cait O’Sullivan, Wade Thompson, Ken Bassett, Josh Levin, Colin R Dormuth. Treatment pattern trends of medications for type 2 diabetes in Briti
Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana H. Y. Yu, Shawn C. Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R.
Following recent patent expirations of originator biologics, their more affordable biosimilar versions became available. Switching patients from originator to its biosimilar as par
